Categories: News

Angelalign Technology Achieves Steady Growth in 2024, Driven by Global Expansion and Digital Innovation

SAN CLEMENTE, Calif., March 20, 2025 /PRNewswire/ — Angelalign Technology Inc. (“Angelalign Technology” or the “Company”) (6699.HK) released its financial results for fiscal year 2024. Driven by rapid expansion in global markets and continued innovation in digital orthodontics, the Company delivered a robust global performance despite complex global market challenges.

In 2024, Angelalign Technology’s global clear aligner case volume grew to approximately 359,400 cases from 245,000 cases the previous year, a 46.7% year-over-year increase. Non-China global markets contributed approximately 140,700 cases, representing 39.1% of the Company’s total annual case volume. This highlights the Company’s growth in these regions. The Company reported a year-over-year total revenue increase of 28.2% to US$268.8 million, with gross profit rising by 28.7% to US$168.2 million and net profit growing by 46.6% to US$10.0 million. Angelalign Technology also maintains a strong balance sheet with US$227.1 million in cash and cash equivalents, enhancing its ability to invest in long-term business growth.

Founded in 2003 by a team of progressive orthodontists, Angelalign Technology has grown into a trusted industry leader with more than one million patients treated. Recognized as a leader in China — the world’s second-largest clear aligner market and a market known for case complexity — the Company stands out in market share and product superiority. Angelalign Technology was listed on the Hong Kong Stock Exchange in 2021. In 2023, Angelalign Technology accelerated its global expansion and formalized its “glocalization” strategy. It now has highly specialized teams in EMEA, Asia-Pacific, and the Americas. By adopting a customer-centric approach, high-quality treatment plans, differentiated product portfolio and features, fast turnaround times, and steady delivery, the Company continues to provide premium products and services to customers worldwide.

Angelalign Technology’s global business spans 50 countries in Europe, Asia-Pacific, and the Americas. In March 2025, the Company announced plans to build a new 52,000-square-foot manufacturing facility in Greater Milwaukee, Wisconsin. Equipped with highly automated proprietary 3D printing technology, the facility will become one of the most advanced clear aligner manufacturing centers in the world. The Company is also expanding treatment planning capacity and aligner production in Brazil, which further strengthens its commitment to localized manufacturing in the Americas.

In 2024, Angelalign Technology attended major international orthodontic conferences in Europe, North America, and the Americas. The Company also launched the Angel Aligner Education App. Angelalign Technology strongly supports KOL-led research publications in international journals to showcase clinical applications and data-driven results of Angel Aligner’s products and medical technology solutions.

While expanding its global presence, Angelalign Technology remains committed to digital innovation by continuously introducing advanced digital tools to enhance high-quality treatment planning, streamline workflow efficiency, and improve clinical outcomes. These advancements reinforce its fast turnaround times and steady delivery.

Fox Hu, CEO of Angelalign Technology, stated: “Our relentless focus on digitalization- and globalization-driven strategies have enabled us to achieve sustained and robust growth. We remain committed to innovation, ever-better clinical outcomes, improved patient experience, and expanded global offerings.”

For more information, please contact Head of Marketing, Sue.Kolb@angelaligner.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/angelalign-technology-achieves-steady-growth-in-2024-driven-by-global-expansion-and-digital-innovation-302407421.html

SOURCE Angelalign Technology Inc.

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

8 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

11 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

11 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

11 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

11 hours ago